Announcement

Collapse
No announcement yet.

The Lancet Infect Dis. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • The Lancet Infect Dis. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial

    [Source: The Lancet Infectious Diseases, full page: (LINK). Abstract, edited.]


    The Lancet Infectious Diseases, Early Online Publication, 22 November 2013

    doi:10.1016/S1473-3099(13)70267-6

    Copyright 2013 Elsevier Ltd All rights reserved.

    Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial

    Original Text

    Dr Alicia M Fry MD a, Doli Goswami MD b, Kamrun Nahar b, Amina Tahia Sharmin MBBS b, Mustafizur Rahmun PhD b, Larisa Gubareva PhD a, Tasnim Azim PhD b, Joseph Bresee MD a, Stephen P Luby MD a b, W Abdullah Brooks MD b


    Summary

    Background

    Influenza causes substantial morbidity and mortality worldwide. Few data exist for the efficacy of neuraminidase inhibitors, which are the only readily available influenza treatment options, especially in low-income settings. We assessed the efficacy of treatment with the neuraminidase inhibitor oseltamivir to reduce patient illness and viral shedding in people with influenza, in whom treatment was started within 5 days of symptom onset, in an urban setting in Bangladesh.


    Methods

    We undertook a double-blind, randomised, controlled trial between May, 2008, and December, 2010. Patients with a positive rapid influenza test identified by surveillance of households in Kamalapur, Bangladesh were randomly allocated on a 1:1 basis to receive oseltamivir or placebo twice daily for 5 days. Randomisation lists for individuals enrolled less than 48 h and 48 h or longer since illness onset were generated with permuted blocks of variable length between two and eight. Participants and study staff were masked to treatment group. Participants provided nasal wash specimens at enrolment and 2, 4, and 7 days later, and were visited daily to record symptoms. All specimens were tested for influenza with reverse-transcriptase PCR, and if the result was positive, we isolated the virus. The primary endpoints were duration of clinical illness and viral shedding in patients treated less than and more than 48 h since illness onset and the frequency of oseltamivir resistance during treatment. Analyses were intention to treat unless otherwise specified. This trial is registered with ClinicalTrials.gov, number NCT00707941.


    Findings

    Overall, 1190 people with a median age of 5 years (IQR 29) were enrolled: 794 (67%) less than 48 h since symptom onset and 396 (33%) 48 h or longer since symptom onset. 592 participants were assigned to placebo and 598 to oseltamivir. The median duration of symptoms was shorter in the oseltamivir group (3 days, IQR 15) than in the placebo group (4 days, 16; p=001). When stratified by timing of treatment initiation, in participants enrolled 48 h or longer since illness onset, the median duration of symptoms was similar in both groups (oseltamivir 3 days [IQR 25], placebo 3 days [15]; p=004). The median duration of symptoms was reduced by 1 day in the group given oseltamivir who were enrolled less than 48 h since symptom onset compared with those given placebo, but this difference was not significant. In those with all swab specimens (n=1134), oseltamivir significantly reduced virus isolation on days 2 (placebo 374 [66%] vs oseltamivir 321 [56%]; difference 152%, 95% CI 95208, p=00004), 4 (241 [43%] vs 174 [30%]; difference 302%, 95% CI 246358, p<00001), and 7 (68 [12%] vs 36 [6%]; difference 475%, 95% CI 442508, p=00009). In participants enrolled 48 h or longer since illness onset, oseltamivir treatment significantly reduced virus isolation on days 2 and 4, but not day 7. In participants enrolled less than 48 h since illness onset, oseltamivir treatment significantly reduced virus isolation on days 2, 4, and 7. The emergency of resistance to oseltamivir during treatment was rare overall (<1%) and in influenza A H1N1pdm09 viruses (39%).


    Interpretation

    Oseltamivir treatment resulted in a modest reduction in the duration of symptoms and virus shedding in people with uncomplicated influenza infections, even when treatment was started 48 h or longer after illness onset.


    Funding

    Centers for Disease Control and Prevention (in agreement with the International Centre for Diarrhoeal Disease Research, Bangladesh).
    ________

    a Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; b International Centre for Diarrhoreal Disease Research Bangladesh, Dhaka, Bangladesh

    Correspondence to: Dr Alicia M Fry, Centers for Disease Control and Prevention, 1600 Clifton Road, MS A-32, Atlanta, GA 30307, USA


    -
    -------
Working...
X